晚期中肠神经内分泌肿瘤患者中[177Lu]Lu-DOTATATE的剂量测定:III期NETTER-1试验子研究结果
该研究为III期NETTER-1试验子研究,评估晚期中肠神经内分泌肿瘤患者接受标准4周期177Lu-DOTATATE方案的剂量学及其与毒性的潜在关系,并探索肿瘤吸收剂量与肿瘤大小变化的关系。20例患者纳入剂量学评估,肾脏和骨髓预测平均累积吸收剂量分别为19.4(SD,8.7)Gy和1.0(SD,0.8)Gy,血液学毒性主要为1-2级且未随时间增加或与累积吸收剂量相关,结论认为标准方案根据急性毒性评估进行个体化调整耐受良好且可管理。
要点
- 20例患者剂量学评估显示器官剂量存在显著患者间变异,肾脏预测平均累积吸收剂量19.4(SD,8.7)Gy,骨髓1.0(SD,0.8)Gy。
- 3例患者肾脏剂量在28至33 Gy之间,其中2例出现1级血清肌酐升高,1例至5年随访无肾脏毒性证据。
- 65个病灶肿瘤动力学显示活性随时间稳定,中位累积吸收剂量134 Gy(范围7-2,218 Gy),大多数肿瘤(90%)在72周研究期内缩小。
核心结论
- 剂量学数据支持以下结论:包含根据急性毒性评估进行个体化调整的177Lu-DOTATATE标准治疗方案耐受良好且可管理。
研究设计与样本
- III期NETTER-1试验的子研究,2013年8月至2016年1月入组局部晚期或转移性、高分化中肠神经内分泌肿瘤患者。
- 患者计划接受4次7.4 GBq的177Lu-DOTATATE输注,累积注入活度为29.6 GBq。
- 输注后采集全身平面图像(4-6个时间点,最长7天)和SPECT/CT图像(24和/或48小时),计算吸收和时间积分活度系数以得出剂量学。
- 采用血液和尿液样本确定血液清除率和活度消除率;肿瘤吸收剂量采用球体模型、基于每个病灶质量插值177Lu剂量因子得出。
- 通过CT测量最长和垂直维度评估肿瘤大小;剂量学评估共纳入20例患者。
主要发现
- 器官剂量学显示显著的 patient 间变异;肾脏和骨髓预测平均累积吸收剂量分别为19.4(SD,8.7)Gy和1.0(SD,0.8)Gy。
- 3例患者肾脏剂量在28至33 Gy之间;2例出现1级血清肌酐升高,1例至5年随访无肾脏毒性证据。
- 血液学毒性主要为轻度或中度(1-2级),未随时间增加,也未与累积吸收剂量相关。
- 65个病灶的肿瘤动力学显示活性随时间稳定;观察到患者间和患者内变异,中位累积吸收剂量为134 Gy(范围7-2,218 Gy)。
- 承认所用影像方法和肿瘤体积评估的局限性,未发现最佳肿瘤大小缩小与吸收剂量之间的相关性,尽管大多数肿瘤(90%)在72周研究期内缩小。
关键数值与推荐
- 标准方案为4次177Lu-DOTATATE输注,每次7.4 GBq,累积注入活度29.6 GBq。
- 肾脏预测平均累积吸收剂量19.4(SD,8.7)Gy,骨髓1.0(SD,0.8)Gy。
- 3例患者肾脏剂量在28至33 Gy之间;2例出现1级血清肌酐升高,1例至5年随访无肾脏毒性证据。
- 血液学毒性主要为1-2级,未随时间增加或与累积吸收剂量相关。
- 65个病灶中位累积吸收剂量134 Gy(范围7-2,218 Gy);大多数肿瘤(90%)在72周研究期内缩小,但未发现最佳肿瘤大小缩小与吸收剂量之间的相关性。
临床怎么用
- 原文结论指出,包含根据急性毒性评估进行个体化调整的177Lu-DOTATATE标准治疗方案耐受良好且可管理。
局限性
- 原文承认所用影像方法和肿瘤体积评估的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This substudy of the phase III NETTER-1 trial evaluated [177Lu]Lu-DOTATATE (hereafter 177Lu-DOTATATE) for advanced midgut neuroendocrine tumors and aimed to assess dosimetry of a standard 4-cycle protocol and any potential relationship to toxicity. Change in tumor size by absorbed dose was an exploratory endpoint. Methods: Patients with locally advanced or metastatic, well-differentiated, midgut neuroendocrine tumors were enrolled in this substudy between August 2013 and January 2016. Patients were scheduled to receive 4 infusions of 7.4 GBq of 177Lu-DOTATATE for a cumulative injected activity of 29.6 GBq. After a 177Lu-DOTATATE infusion, whole-body planar images (4-6 time points for up to 7 d) and SPECT/CT images (at 24 and/or 48 h) were acquired, and absorbed and time-integrated activity coefficients were calculated to derive dosimetry. Blood and urine samples were used to determine the blood clearance and activity elimination rate. Tumor absorbed dose was derived using a sphere model, interpolating 177Lu dose factors on the basis of each lesion mass. Tumor size was assessed by measuring the longest and perpendicular dimensions on CT at measured time points. Results: Dosimetric assessments were evaluated in 20 patients. Organ dosimetry showed substantial interpatient variability. The predicted mean cumulative absorbed doses to kidneys and bone marrow were 19.4 (SD, 8.7) and 1.0 (SD, 0.8) Gy, respectively. Three patients had kidney doses between 28 and 33 Gy; 2 had grade 1 increased serum creatinine, and 1 showed no evidence of renal toxicity (up to 5 y of follow-up). Hematologic toxicity was primarily mild or moderate (grade 1-2) with no increase over time or association with cumulative absorbed dose. Tumor kinetics in 65 lesions demonstrated stable activity over time. Inter- and intrapatient variability was observed, and the median cumulative absorbed dose was 134 Gy (range, 7-2,218 Gy). Acknowledging the limitations of the imaging methods used and tumor volume assessments, we found no correlation between the best tumor size reduction and the absorbed dose, though most tumors (90%) shrank over the 72-wk study period. Conclusion: The dosimetry data support the findings that the standard treatment regimen with 177Lu-DOTATATE that includes personalized adjustments according to acute toxicity assessments is well tolerated and manageable.
引用
- Bodei L, Cremonesi M, Ferrari M, et al. Dosimetry of [177Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumors: Results from a Substudy of the Phase III NETTER-1 Trial. J Nucl Med. 2025. PMID: 39947918. doi:10.2967/jnumed.124.268903
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。